Alliance for Clinical Trials in Oncology shared on LinkedIn:
“New trial. A more personalized approach.
Alliance Foundation Trials and Natera announce AFT-70 NAVIGATE, a global Phase III trial for patients with ER+/HER2- early-stage breast cancer.
The study will use Signatera MRD testing to help guide CDK4/6 inhibitor treatment alongside giredestrant, Genentech’s investigational oral SERD – with the goal of identifying patients who may be able to avoid unnecessary treatment and its associated toxicities.
Learn more: Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE.”
To which Natera added:
“This is incredibly important research that will use Signatera to help individualize treatment for patients with breast cancer.
We’re proud to support this work alongside Alliance for Clinical Trials in Oncology and Genentech, and grateful to the patients and investigators making it possible.”
Other articles about Alliance for Clinical Trials in Oncology and breast cancer on OncoDaily.